Study on Immunotherapy Treatment for Ovarian Cancer and Other Advanced Cancers

Inclusion Criteria

• Adults aged 18 and older with advanced solid tumors that cannot be removed by surgery.
• Tumors must show a specific protein called NY-ESO-1.
• Patients must have tried at least two standard treatments, such as chemotherapy or immunotherapy, and either not responded or been unable to continue them.
• Specific criteria for different types of cancer, such as ovarian cancer, soft tissue sarcoma, and others, must be met.
• Patients must have a life expectancy of more than 3 months.
• Must have at least one measurable tumor.
• Must be willing to provide a tumor sample for testing.
• Must have a specific genetic marker called HLA-A*0201.
• Must have normal organ and blood function based on specific tests.
• Women of childbearing potential must agree to use effective birth control during the study and for 6 to 12 months after.
• Must be able to understand and sign a consent form.
• Must have a caregiver available and live within 45 minutes of the study site for a period after hospital discharge.

Exclusion Criteria

• Currently receiving other experimental treatments.
• History of severe allergic reactions to similar treatments.
• Uncontrolled illnesses, such as heart failure or active infections.
• Active autoimmune diseases requiring high doses of steroids.
• History of certain bowel diseases or current colitis.
• Need for systemic steroids or immunosuppressive drugs.
• Active brain metastases unless previously treated and stable.
• Dementia or mental conditions affecting consent or compliance.
• Pregnant or breastfeeding women.
• Lack of availability for follow-up assessments.
• Abnormal lung function or low oxygen levels.
• History of lung diseases like pneumonitis.
• Fluid buildup in the body requiring frequent drainage.
• Recent major surgery or live vaccines within 30 days before the study.